We are live on ! Find out more
ENSC icon

Ensysce Biosciences
ENSC

13 hedge funds and large institutions have $138K invested in Ensysce Biosciences in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

10.11% less ownership

Funds ownership: 10.11% → 0% (-10%)

19% less funds holding

Funds holding: 16 → 13 (-3)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

42% less capital inflows, than outflows

Capital inflows: $419K | Capital outflows: $721K

Holders
13
Holders Change
-3
Holders Change %
-18.75%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
1
Reduced
–
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$112K
2
Two Sigma Investments
Two Sigma Investments
New York
+$105K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$70.3K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$46.5K
5
Millennium Management
Millennium Management
New York
+$38K

Top Sellers

Rank Fund Capital Flow
1
HG Vora Capital Management
HG Vora Capital Management
New York
-$529K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$68K
3
Cerity Partners
Cerity Partners
New York
-$32K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$28K
5
Moneta Group Investment Advisors
Moneta Group Investment Advisors
Missouri
-$22K

ENSC Hedge Fund Activity: Q4 2022 in Review

13 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q4 2022, worth a combined $138K — down 83% from $833K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ENSC and 8 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $112K. The largest seller was HG Vora Capital Management, exiting entirely with an estimated $529K sold.

  • 13 institutional investors held Ensysce Biosciences (ENSC) as of Q4 2022, down from 16 in Q3 2022.
  • Funds reported $138K of Ensysce Biosciences stock for Q4 2022, down 83% quarter-over-quarter.
  • 8 funds opened new Ensysce Biosciences positions in Q4 2022 and 11 closed out, a net change of -3 holders.
  • The largest Ensysce Biosciences buyer in Q4 2022 was Citadel Advisors, an estimated $112K added.
  • The largest Ensysce Biosciences seller in Q4 2022 was HG Vora Capital Management, an estimated $529K sold.

Based on aggregated 13F filings for Q4 2022.